Modelling overdispersion and Markovian features in count data.

Abstract:

:The number of counts (events) per unit of time is a discrete response variable that is generally analyzed with the Poisson distribution (PS) model. The PS model makes two assumptions: the mean number of counts (lambda) is assumed equal to the variance, and counts occurring in non-overlapping intervals are assumed independent. However, many counting outcomes show greater variability than predicted by the PS model, a phenomenon called overdispersion. The purpose of this study was to implement and explore, in the population context, different distribution models accounting for overdispersion and Markov patterns in the analysis of count data. Daily seizures count data obtained from 551 subjects during the 12-week screening phase of a double-blind, placebo-controlled, parallel-group multicenter study performed in epileptic patients with medically refractory partial seizures, were used in the current investigation. The following distribution models were fitted to the data: PS, Zero-Inflated PS (ZIP), Negative Binomial (NB), and Zero-Inflated Negative Binomial (ZINB) models. Markovian features were introduced estimating different lambdas and overdispersion parameters depending on whether the previous day was a seizure or a non-seizure day. All analyses were performed with NONMEM VI. All models were successfully implemented and all overdispersed models improved the fit with respect to the PS model. The NB model resulted in the best description of the data. The inclusion of Markovian features in lambda and in the overdispersion parameter improved the fit significantly (P < 0.001). The plot of the variance versus mean daily seizure count profiles, and the number of transitions, are suggested as model performance tools reflecting the capability to handle overdispersion and Markovian features, respectively.

authors

Trocóniz IF,Plan EL,Miller R,Karlsson MO

doi

10.1007/s10928-009-9131-y

subject

Has Abstract

pub_date

2009-10-01 00:00:00

pages

461-77

issue

5

eissn

1567-567X

issn

1573-8744

journal_volume

36

pub_type

杂志文章,多中心研究,随机对照试验
  • A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation.

    abstract::The citalopram for Alzheimer's disease trial evaluated citalopram for the management for agitation in Alzheimer's disease patients. Sparse data was available from this elderly patient population. A nonlinear mixed effects population pharmacokinetic modeling approach was used to describe the pharmacokinetics of R- and ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-015-9457-6

    authors: Akil A,Bies RR,Pollock BG,Avramopoulos D,Devanand DP,Mintzer JE,Porsteinsson AP,Schneider LS,Weintraub D,Yesavage J,Shade DM,Lyketsos CG

    更新日期:2016-02-01 00:00:00

  • Predicting the F(ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modelling.

    abstract::Cell-level kinetic models for therapeutically relevant processes increasingly benefit the early stages of drug development. Later stages of the drug development processes, however, rely on pharmacokinetic compartment models while cell-level dynamics are typically neglected. We here present a systematic approach to int...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-012-9243-7

    authors: Krippendorff BF,Oyarzún DA,Huisinga W

    更新日期:2012-04-01 00:00:00

  • Population pharmacokinetics of amodiaquine and desethylamodiaquine in pediatric patients with uncomplicated falciparum malaria.

    abstract::The study aimed to characterize the population pharmacokinetics of amodiaquine (AQ) and its major metabolite N-desethylamodiaquine (N-DEAQ), and to assess the correlation between exposure to N-DEAQ and treatment outcome. Blood samples from children in two studies in Zanzibar and one in Papua New Guinea were included i...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-007-9064-2

    authors: Hietala SF,Bhattarai A,Msellem M,Röshammar D,Ali AS,Strömberg J,Hombhanje FW,Kaneko A,Björkman A,Ashton M

    更新日期:2007-10-01 00:00:00

  • Propagation of population pharmacokinetic information using a Bayesian approach: comparison with meta-analysis.

    abstract::We investigated the propagation of population pharmacokinetic information across clinical studies by applying Bayesian techniques. The aim was to summarize the population pharmacokinetic estimates of a study in appropriate statistical distributions in order to use them as Bayesian priors in consequent population pharm...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-005-0048-9

    authors: Dokoumetzidis A,Aarons L

    更新日期:2005-08-01 00:00:00

  • Quantitative systems pharmacology as an extension of PK/PD modeling in CNS research and development.

    abstract::Quantitative systems pharmacology (QSP) is a recent addition to the modeling and simulation toolbox for drug discovery and development and is based upon mathematical modeling of biophysical realistic biological processes in the disease area of interest. The combination of preclinical neurophysiology information with c...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-013-9297-1

    authors: Geerts H,Spiros A,Roberts P,Carr R

    更新日期:2013-06-01 00:00:00

  • Evaluation of performance of distributed delay model for chemotherapy-induced myelosuppression.

    abstract::The distributed delay model has been introduced that replaces the transit compartments in the classic model of chemotherapy-induced myelosuppression with a convolution integral. The maturation of granulocyte precursors in the bone marrow is described by the gamma probability density function with the shape parameter (...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-018-9575-z

    authors: Krzyzanski W,Hu S,Dunlavey M

    更新日期:2018-04-01 00:00:00

  • A stochastic model describes the heterogeneous pharmacokinetics of cyclosporin.

    abstract::The pharmacokinetics of cyclosporin (CsA) are unusual because of several heterogeneous features which include the presence of more than one conformer, considerable accumulation in erythrocytes and lipoproteins, extensive plasma protein binding, distribution into deep tissues, biliary secretion and hepatic clearance in...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1023/a:1012295014352

    authors: Claret L,Iliadis A,Macheras P

    更新日期:2001-10-01 00:00:00

  • A reduction in between subject variability is not mandatory for selecting a new covariate.

    abstract::Population pharmacokinetic-pharmacodynamic analysis involves nonlinear hierarchical modelling where the mean response in a population and the variability in response from different sources are studied. It generally consists of two model hierarchies: a model for residual error and a model for heterogeneity termed betwe...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-012-9256-2

    authors: Lagishetty CV,Vajjah P,Duffull SB

    更新日期:2012-08-01 00:00:00

  • Introduction to the analysis of PET data in oncology.

    abstract::Several reviews on specific topics related to positron emission tomography (PET) ranging in complexity from introductory to highly technical have already been published. This introduction to the analysis of PET data was written as a simple guide of the different phases of analysis of a given PET dataset, from acquisit...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章,评审

    doi:10.1007/s10928-013-9307-3

    authors: Tomasi G,Aboagye EO

    更新日期:2013-08-01 00:00:00

  • Challenges of a mechanistic feedback model describing nicotinic acid-induced changes in non-esterified fatty acids in rats.

    abstract::Previously, we developed a feedback model to describe the tolerance and oscillatory rebound of non-esterified fatty acid (NEFA) plasma concentrations in male Sprague Dawley rats after intravenous infusions of nicotinic acid (NiAc). This study challenges that model, using the following regimens of intravenous and oral ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-013-9325-1

    authors: Ahlström C,Peletier LA,Gabrielsson J

    更新日期:2013-08-01 00:00:00

  • Benchmarking renin suppression and blood pressure reduction of direct renin inhibitor imarikiren through quantitative systems pharmacology modeling.

    abstract::Multiple classes of antihypertensive drugs inhibit components of the renin-angiotensin-aldosterone system (RAAS). The primary physiological effector of the RAAS is angiotensin II (AngII) bound to the AT1 receptor (AT1-bound AngII). There is a strong non-linear feedback from AT1-bound AngII on renin secretion. Since AT...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-018-9612-y

    authors: Gebremichael Y,Lahu G,Vakilynejad M,Hallow KM

    更新日期:2019-02-01 00:00:00

  • Robust population pharmacokinetic experiment design.

    abstract::The population approach to estimating mixed effects model parameters of interest in pharmacokinetic (PK) studies has been demonstrated to be an effective method in quantifying relevant population drug properties. The information available for each individual is usually sparse. As such, care should be taken to ensure t...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-005-2102-z

    authors: Dodds MG,Hooker AC,Vicini P

    更新日期:2005-02-01 00:00:00

  • Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effects.

    abstract::Mathematical modeling of drug effects maximizes the information gained from an experiment, provides further insight into the mechanisms of drug effects, and allows for simulations in order to design studies or even to derive clinical treatment strategies. We reviewed modeling of antimicrobial drug effects and show tha...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章,评审

    doi:10.1007/s10928-007-9069-x

    authors: Czock D,Keller F

    更新日期:2007-12-01 00:00:00

  • Potential errors in the volume of distribution estimation of therapeutic proteins composed of differently cleared components.

    abstract::The volume of distribution at steady state (Vss) of therapeutic proteins is usually assessed by non-compartmental or compartmental pharmacokinetic (PK) analysis wherein errors may arise due to the elimination of therapeutic proteins from peripheral tissues that are not in rapid equilibrium with the sampling compartmen...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-011-9209-1

    authors: Richter WF,Grimm HP,Theil FP

    更新日期:2011-10-01 00:00:00

  • Comparison of proportional and differential odds models for mixed-effects analysis of categorical data.

    abstract::In this work a model for analyzing categorical data is presented; the differential odds model. Unlike the commonly used proportional odds model, this model does not assume that a covariate affects all categories equally on the log odds scale. The differential odds model was compared to the proportional odds model, by ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-008-9098-0

    authors: Kjellsson MC,Zingmark PH,Jonsson EN,Karlsson MO

    更新日期:2008-10-01 00:00:00

  • Optimization of clinical dosing schedule to manage neutropenia: learnings from semi-mechanistic modeling simulation approach.

    abstract::Neutropenia is a common side-effect of oncology drugs. We aimed to study the impact of exposure and dosing schedule on neutropenia to guide selection of dosing schedules that minimize neutropenia potential while maintaining the desired minimum concentration (Cmin) required for target engagement. Dose, frequency and PK...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-019-09667-y

    authors: Guo Y,Haddish-Berhane N,Xie H,Ouellet D

    更新日期:2020-02-01 00:00:00

  • A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus.

    abstract::Effective long-term treatment of Type 2 Diabetes Mellitus (T2DM) implies modification of the disease processes that cause this progressive disorder. This paper proposes a mechanism-based approach to disease progression modeling of T2DM that aims to provide the ability to describe and quantify the effects of treatment ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-006-9008-2

    authors: de Winter W,DeJongh J,Post T,Ploeger B,Urquhart R,Moules I,Eckland D,Danhof M

    更新日期:2006-06-01 00:00:00

  • Assessing the dynamics of nuclear glucocorticoid-receptor complex: adding flexibility to gene expression modeling.

    abstract::A retrospective analysis was performed to modify our fourth-generation pharmacodynamic model for glucocorticoid receptor (GR) dynamics with incorporation of more physiological features. This modified model was developed by integrating previously reported free cytosolic GR and GR mRNA data following single (10, 50 mg/k...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-007-9049-1

    authors: Hazra A,DuBois DC,Almon RR,Jusko WJ

    更新日期:2007-06-01 00:00:00

  • Understanding the linked kinetics of benzo(a)pyrene and 3-hydroxybenzo(a)pyrene biomarker of exposure using physiologically-based pharmacokinetic modelling in rats.

    abstract::3-hydroxybenzo(a)pyrene (3-OHBaP) in urine has been proposed as a biomarker of occupational exposure to polycyclic aromatic hydrocarbons. However, to reconstruct exposure doses in workers from biomarker measurements, a thorough knowledge of the kinetics of the benzo(a)pyrene (BaP) and 3-OHBaP given different routes of...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-013-9338-9

    authors: Heredia-Ortiz R,Bouchard M

    更新日期:2013-12-01 00:00:00

  • A mathematical model for paroxetine antidepressant effect time course and its interaction with pindolol.

    abstract::Although selective 5-HT reuptake inhibitors (SSRIs) block monoamine uptake within hours of administration to patients, their full clinical effect does not appear until 2-4 weeks after treatment onset. Pindolol, a betablocker with weak partial 5-HT1A receptor agonist activity has been shown to produce a more rapid onse...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-005-0006-6

    authors: Gruwez B,Dauphin A,Tod M

    更新日期:2005-12-01 00:00:00

  • Modeling T cell responses to antigenic challenge.

    abstract::T cell responses are a crucial part of the adaptive immune system in the fight against infections. This article discusses the use of mathematical models for understanding the dynamics of cytotoxic T lymphocyte (CTL) responses against viral infections. Complementing experimental research, mathematical models have been ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章,评审

    doi:10.1007/s10928-014-9387-8

    authors: Wodarz D

    更新日期:2014-10-01 00:00:00

  • Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression.

    abstract:AIM:Chemotherapy with indisulam causes myelosuppression. This study aimed to evaluate the influence of patient-related covariates on pharmacokinetics and pharmacodynamics, to identify patients at risk for severe myelosuppression and to develop a dosing algorithm for treatment optimization. METHODS:Pharmacokinetic and ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-009-9111-2

    authors: Zandvliet AS,Schellens JH,Copalu W,Beijnen JH,Huitema AD

    更新日期:2009-02-01 00:00:00

  • Physiologically-based modeling and interspecies prediction of paclitaxel pharmacokinetics.

    abstract::The objective was to develop a physiologically-based pharmacokinetic (PBPK) model to characterize the whole-body disposition of paclitaxel (formulated in Cremophor EL and ethanol-Taxol®) in mice and to evaluate the utility of this model for predicting pharmacokinetics in other species. Published studies that reported ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-018-9586-9

    authors: Zang X,Kagan L

    更新日期:2018-08-01 00:00:00

  • Population pharmacokinetics of intravenous acetaminophen and its metabolites in major surgical patients.

    abstract::Intravenous acetaminophen is a commonly used analgesic following surgery. The aims of this study were to determine the population pharmacokinetic profile of intravenous acetaminophen and its metabolites in adult surgical patients and to identify patient characteristics associated with acetaminophen metabolism in the p...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-014-9358-0

    authors: Owens KH,Murphy PG,Medlicott NJ,Kennedy J,Zacharias M,Curran N,Sreebhavan S,Thompson-Fawcett M,Reith DM

    更新日期:2014-06-01 00:00:00

  • The design and analysis of parallel experiments to produce structurally identifiable models.

    abstract::Pharmacokinetic analysis in humans using compartmental models is restricted with respect to the estimation of parameter values. This is because the experimenter usually is only able to apply inputs and observations in a very small number of compartments in the system. This has implications for the structural identifia...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-012-9291-z

    authors: Cheung SY,Yates JW,Aarons L

    更新日期:2013-02-01 00:00:00

  • Modeling cancer-immune responses to therapy.

    abstract::Cancer therapies that harness the actions of the immune response, such as targeted monoclonal antibody treatments and therapeutic vaccines, are relatively new and promising in the landscape of cancer treatment options. Mathematical modeling and simulation of immune-modifying therapies can help to offset the costs of d...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-014-9386-9

    authors: dePillis LG,Eladdadi A,Radunskaya AE

    更新日期:2014-10-01 00:00:00

  • Pharmacodynamic analysis of changes in reticulocyte subtype distribution in phlebotomy-induced stress erythropoiesis.

    abstract::Changes in the reticulocyte subtype distribution (high, medium and low reticulocytes count (HR, MR, LR)) measured by flow cytometry following phlebotomy-induced stress erythropoiesis (abruptly dropping hemoglobin to 3-4 g/dl over 4-5 hr) and the pharmacodynamic (PD) relationship to the stimulated erythropoietin (EPO) ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-005-0009-3

    authors: Al-Huniti NH,Widness JA,Schmidt RL,Veng-Pedersen P

    更新日期:2005-08-01 00:00:00

  • Evaluation of false positive rate based on exposure-response analyses for two compounds in fixed-dose combination products.

    abstract::We explored the type I error rate (false positive rate) associated with exposure-response (ER) analyses for two compounds in a fixed-dose combination product through simulations. In the simulations, at least one compound was assumed to be inactive, whereas the active compound followed E(max) model at different concent...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-011-9214-4

    authors: Zhu H,Wang Y

    更新日期:2011-12-01 00:00:00

  • Population pharmacokinetic-pharmacodynamic modeling of filgrastim (r-metHuG-CSF) in healthy volunteers.

    abstract::The pharmacokinetic-pharmacodynamic (PK-PD) relationship of the granulopoietic effects of Filgrastim in healthy volunteers was characterized via a population approach. Healthy male volunteers were enrolled into a four-way crossover clinical trial. Subjects received four single doses of Filgrastim (375 and 750 microgra...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1023/a:1011534529622

    authors: Wang B,Ludden TM,Cheung EN,Schwab GG,Roskos LK

    更新日期:2001-08-01 00:00:00

  • Is mixed effects modeling or naïve pooled data analysis preferred for the interpretation of single sample per subject toxicokinetic data?

    abstract::The purpose of this study was to evaluate whether mixed effects modeling (MEM) performs better than either noncompartmental or compartmental naïve pooled data (NPD) analysis for the interpretation of single sample per subject pharmacokinetic (PK) data. Using PK parameters determined during a toxicokinetic study in rat...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1023/a:1011507100493

    authors: Hing JP,Woolfrey SG,Greenslade D,Wright PM

    更新日期:2001-04-01 00:00:00